Form 4: Intellia Director Frank Verwiel Receives Equity Grant

Director Frank Verwiel was granted 9,200 restricted stock units and 13,300 stock options by Intellia Therapeutics.

Summary

• Director Frank Verwiel received a grant of 9,200 restricted stock units (RSUs) on June 9, 2026.
• The director was also granted 13,300 stock options with an exercise price of $12.89 per share.
• The stock options vest in full on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders.
• Following these transactions, the director's total beneficial ownership of common stock increased to 35,148 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on the company's financial outlook.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The issuance of equity grants results in minor dilution to existing shareholders.

Risks

• Market volatility affecting the value of equity-based compensation.
• Potential for future dilution if additional equity grants are issued to board members or employees.

Future Outlook

The filing does not provide forward-looking financial guidance, focusing solely on director compensation.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain board expertise while aligning incentives with company performance.

Comparison to Industry Standards

• The grant structure is consistent with standard corporate governance practices for mid-cap biotechnology firms.
• Vesting schedules align with typical annual director compensation cycles observed in the industry.

Stakeholder Impact

• Minor dilution for existing shareholders due to the issuance of new equity.

Next Steps

• Vesting of stock options on the earlier of June 9, 2027, or the next annual meeting of stockholders.

Key Dates

Keywords

Intellia Therapeutics, NTLA, Form 4, Insider Transaction, Equity Grant, Biotech